Screener
Neurocrine Biosciences NBIX Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Capital expenditures | (9.1) | (10.7) |
| Cash flows from investing activities | (506.2) | 14.2 |
| Cash flows from financing activities: | ||
| Issuances of common stock under benefit plans | 23.6 | 32.1 |
| Taxes paid related to net share settlement of equity awards | (55.7) | — |
| Repurchases of common stock | (54.0) | (150.0) |
| Cash flows from financing activities | (86.1) | (117.9) |
| Change in cash, cash equivalents and restricted cash | (446.5) | (38.9) |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's stock issuance proceeds?
- Neurocrine Biosciences (NBIX) reported stock issuance proceeds of $23.6M in Q1 2026.
- How has Neurocrine Biosciences's stock issuance proceeds changed year-over-year?
- Neurocrine Biosciences's stock issuance proceeds decreased by 26.5% year-over-year, from $32.1M to $23.6M.
- What is the long-term trend for Neurocrine Biosciences's stock issuance proceeds?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's stock issuance proceeds has grown at a 47.3% compound annual growth rate (CAGR), from $27.5M to $129.4M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about Neurocrine Biosciences's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude